Correlation between Serum Quantitative HBsAG and HBV-DNA Levels with Histological Activity Index and Hepatic HBsAG Expression in Liver Biopsy Specimens of Patients with Treatment Naive Chronic Viral Hepatitis B Infection (original) (raw)
Related papers
International Journal of Medical Science and Clinical Invention, 2023
Introduction: We aimedto analyze the correlations between serum HBsAg quantification (qHBsAg) level and virological properties in chronic hepatitis B (CHB) patients. Materials and Methods: The study was conducted with 53 CHB patients who underwent liver biopsy. Demographic characteristics of patients, biochemical parameters, serum qHBsAg levels, liver biopsy, and histopathology were assessed retrospectively. Results: A total of 53 patients were included in the study the mean patient age was 28,7 ± 8.1 and 34 (64.2%) were male. The mean patient qHBsAg was 631.4 ± 431.5, fibrosis score was 1,35 ± 0.87, ALT index score was 67.1 ± 53.4, and histologic activity index (HAI) score was 4,54 ± 1.55. In the statistical analysis, it was determined that there were negative correlations between the serum qHBsAg level and the HBV DNA level (r: -0,618, P<0.001), fibrosis score (r: -0,273, P: 0.048), ALT (rho: -0,489, P<0.001), and HAI index scores (r: -363, P: 0.008), while there was a positive correlation with the HBeAg positivity (rho: 0.445, p: 0.001). Conclusion: There were negative correlations between the qHBsAg level and virological (HBV DNA level), histopathological (fibrosis score, HAI index) findings, and a positive correlation with serological (HBeAg positivity) findings. Keywords: Quantitative, qHBsAg, Hepatitis B, Chronic hepatitis.
Journal of Clinical and Experimental Hepatology, 2016
Background/objective: Quantification of serum hepatitis B antigen (HBsAg) is an important test that marks active infection with hepatitis B and helps in the prediction of the clinical outcome and management of hepatitis B virus (HBV) infection. Correlation with HBV DNA quantitative levels may help in developing strategies for antiviral treatment. This study is aimed to evaluate HBsAg titres in various phase of HBV infection in HBsAg positive patients, and its correlation with HBV DNA viral load levels. Methods: 976 HBV related patients were analysed in this retrospective cross-sectional study. Patients were categorised on the basis of the phase of HBV infection: immune tolerant phase (IT, n = 123), immune clearance phase (IC, n = 192), low-replicative phase (LR, n = 476), and HBeAg-negative hepatitis (ENH, n = 185). HBsAg titres were quantified and correlated with HBV-DNA levels and clinical parameters. Results: Median HBsAg titres were different between each phases of HBV infection (P < 0.001): (4.62 log10 IU/ml), IC (3.88 log10 IU/ml), LR (2.76 log10 IU/ml) and ENH (2.94 log10 IU/ml). HBsAg and HBV DNA levels showed significant correlation in the whole group (r = 0.694, P < 0.001), and this was also observed in different phases of HBV infection. Strong correlation in IT phase (r = 0.603, P < 0.001) and IC phase (r = 0.523, P < 0.001), moderate in LR phase (r = 0.362, P < 0.001) and weak in ENH (r = 0.110, P = 0.04). No correlation was observed between serum HBsAg levels and biochemical parameters. Conclusion: The study demonstrated significant difference in the median baseline values of serum HBsAg titres in different phases of HBV infection and provides additional information in understanding the natural history of HBV-infection.
Journal of Liver Research, Disorders & Therapy, 2016
Background: Quantitative HBsAg (qHBsAg) level is increasingly recognized as an important marker in the course of HBV infection; however, its role in natural history of disease is still unclear. Aim: To study the baseline serum qHBsAg level and its association with quantitative HBV DNA levels in different phases of Indian chronic hepatitis B (CHB) patients. Materials: We conducted cross-sectional study of consecutive 120CHB patients (mean age 37 [SD 13]years, 67% males). HBV DNA was measured by RT PCR and serum qHBsAg levels by Abott Architect Assay. Results: 90.8% were HBe-negative patients. Median serum qHBsAg of study cohort was 3.74log10 IU/mL. Overall correlation between qHBsAg levels and HBV DNA levels was weak (spearmen r=0.298) and also in HBe-negative patients (r=0.179). Patient having qHBsAg/HBV DNA ratio >49.09 have shown good correlation between qHBsAg levels and HBV DNA levels. Conclusion: Quantitative HBsAg level was widely distributed among the different phases of CHB. Serum qHBsAg may not replace serum HBV DNA test in majority of adult CHB population which are mainly in HBe-negative low replicate stage.
Hepatology, 1985
The correlation between serum and hepatic markers of hepatitis B virus (HBV) has been studied in 70 subjects with chronic active hepatitis of whom 18 were HBsAg' and 52 were HBsAg-. In HBsAg+ subjects, sera were tested for HBeAg/anti-HBe status and for HBV DNA sequences using a DNA dot hybridization technique. Anti-HBs and anti-HBc were measured in serum in the HBsAggroup. Immunoperoxidase staining was used to detect HBsAg, HBcAg and delta antigen in liver tissue. Of the 18 HBsAg+ patients, 13 were HBeAg+ and 5 were anti-me+. A good correlation was shown between HBeAg and HBV DNA in serum and HBcAg expression in liver tissue. Neither HBV DNA in serum nor HBcAg in liver tissue was detected in any of the anti-HBe+ patients. HBsAg and/or HBcAg were detected in liver tissue in 17 of 18 HBsAg+ subjects (95%). However, neither HBsAg nor HBcAg were detected in liver tissue in 52 HBsAg-patients. This group included 11 patients with antibody markers in serum of past HBV infection. Thus, in contrast to previous studies, a good correlation was demonstrated between the serum and hepatic markers of viral replication, and no evidence was obtained to implicate the HBV as an etiological agent in HBsAgchronic active hepatitis.
Authorea (Authorea), 2021
In recent years, several studies suggested that HBsAg titers in blood samples obtained during Hepatitis B treatment could be used to estimate the treatment outcomes. The present study aims to discuss the correlation between HBsAg quantification levels and the virological, serological and histopathological findings in chronic hepatitis B patients.The study included chronic hepatitis B patients who underwent liver biopsy between 2011 and 2013 at Dicle University, Faculty of Medicine, Infectious Diseases and Clinical Microbiology Clinic.. The patient demographics were recorded (age, gender). Patient AST tests were conducted with the spectrophotometric method. After the DNAs were isolated with AmplipPrep Total Nucleic Acid Isolation Kit, DNA level was determined with the COBAS® Amplip / Cobas® Taqman® HBV test V2.0 for HBV. The patient HBV DNA levels were recorded as IU / ml. HBsAg quantitation was studied with the Access device and the Elisa method.The study was conducted with 53 patients. The mean patient age was 28,73 ± 8.15. Out of the 53 patients, 35 (66%) were male and 18 (34%) were female. The mean patient HBsAg quantitation was 631,42 ± 406.55, fibrosis score was 1,35 ± 0.87, ALT index score was 67,07 ± 53.37, and HAI index score was 4,54 ± 1.55. In the statistical analysis, it was determined that there were negative correlations between the HBsAg DNA level
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
Hepatology, 2002
The goals of this retrospective study were to determine whether there is a threshold hepatitis B virus (HBV) DNA value associated with spontaneous or antiviral therapy-related hepatitis B e antigen (HBeAg) clearance. We also investigated whether there is an HBV DNA value that can be used for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis B. HBV DNA levels in sequential serum samples of 165 Chinese patients with different stages of chronic HBV infection were quantified by a polymerase chain reaction (PCR)-based assay. Our results showed that almost all of the patients (83%) who remained HBeAg-positive had HBV DNA levels that were persistently above lo5 copies/mL. Serum HBV DNA levels decreased by a mean of 3 loglo in patients with HBeAg loss, but 5 1% had levels above lo5 copies/mL at the time HBeAg first became undetectable. Mean serum HBV DNA levels were significantly lower in HBeAg-negative patients. HBV DNA value above lo5 copies/mL would exclude all inactive carriers, but 45% of patients with HBeAgnegative chronic hepatitis would also be excluded if testing were only performed at presentation and 30% would be excluded if testing were performed on 3 occasions. In conclusion, serum HBV DNA levels decreased significantly in patients with HBeAg loss, but there was no threshold HBV DNA level associated with HBeAg clearance. Given the fluctuating course of HBeAg-negative chronic hepatitis, it is not possible to define a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis. he evaluation of patients with hepatitis B virus (HBV) infection has evolved from serologic to T molecular diagnostic assays. Using polymerase chain reaction (PCR) assays, the vast majority of patients with chronic HBV infection, including those who are hepatitis B e antigen (HBeAg) negative and hepatitis B e antibody (anti-HBe) positive have detectable HBV DNA in ~erum.~-7 The improvement in sensitivity of HBV Abbreviations: HBI.: hepatitis B virus; PCR, polymerase chain reaction; HBeAg, hepatitis B e antigen; anti-HBe, hepatitis B e antibody; AL T, alanine arninotransferase; HBsAg, hepatitis B su$ace antigen; IFN, interferon.
Evaluation of Chronic Hepatitis B Infection in Patients with Seronegative HbsAg
Iranian journal of public health, 2012
It is estimated that about 370 million people are chronic carriers of HBV worldwide. Apparently 3% of Iranian populations are chronic carriers of this virus. We aimed to evaluate the viral DNA in biological fluids of chronic hepatitis patients compared to a control group. The current case-control study was designed to evaluate the viral DNA in biological fluids of 70 chronic hepatitis patients compared to a control group using ELISA, PCR and Real Time. All individuals (100%) in case group were HBsAg positive while in control group only 2 individuals (2.8%) were HBsAg positive. Three individuals, in control group were positive using PCR and Real Time PCR indicating that about 7% of those in control group were chronic carriers of HBV. The interesting point was the copy of viral DNA; (5.49 ×10(4), 2.162×10(3) and 7.26×10(6)) for 3 chronic carriers using sera while it was about (5.71×10(3), 1.45×10(2) and 2.56×10(5)) using ear cerumen confirming the necessity of investigating for the ca...
Correlation between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients
Vojnosanitetski Pregled, 2023
Background/Aim. Quantitative hepatitis B virus (HBV) surface antigen (qHBsAg) has become increasingly widespread in the last few years in both diagnostic and therapeutic protocols for HBV infection. Numerous studies have proposed it as a surrogate marker for covalently closed circular DNA (cccDNA). The aim of the study was to determine the correlation between qHBsAg and HBV DNA viremia in untreated patients. Methods. The study included 112 untreated patients diagnosed with chronic HBV infection. Demographic and other data from medical records and laboratory analyses, taken as part of routine chronic HBV infection diagnosis with the determination of qHBsAg and HBV DNA viremia, were recorded for all patients. Results. The average age of the patients included in the study was 48.27 ± 15.14 years; males (58%) were more represented. qHBsAg levels had a high-intensity positive correlation with HBV DNA viremia. The concentration of qHBsAg, HBV DNA viremia, and the concentrations of alanine aminotransferase and aspartate aminotransferase showed statistically significantly higher values in HBV e antigen (HBeAg)-positive than in HBeAg-negative patients. Conclusion. Our study showed that qHBsAg has a highintensity positive correlation with HBV DNA viremia. The use of qHBsAg is essential for determining the phase of chronic HBV infection, assessment of the success and length of treatment, as well as for safe discontinuation of antiviral therapy with a lower risk of relapse.
The Evaluation of Quantitative Hbsag Assay and HBV-DNA Assay in Chronic Hepatitis B Infection
2021
Chronic hepatitis B infection increases the risk of developing liver failure, liver cancer or cirrhosis, leading to death in case of bad management of the infection. Polymerase chain reaction assays for measuring HBV DNA has been used for many years for diagnosis and monitoring purposes in patients with chronic hepatitis B, but they are too expensive. Quantitative Hepatitis B Surface Antigen (HBsAg) had been suggested as a similar biomarker with HBV DNA. Recent studies and emerging data have shown that HBsAg levels change dynamically during the natural course of a chronic HBV infection. The aims of this study are to show the correlation between quantitative HBsAg and HBV-DNA levels and to analyze if quantitative HBsAg assay can possibly substitute HBV-DNA assay to optimize the management of chronic hepatitis B patients in our daily clinical practice. A total of 200 samples (52 females and 148 males) from different patients with chronic hepatitis B infection, without starting the tre...